2012

Hamilton, A. et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119 (6). pp. 1501-1510. ISSN 0006-4971 (doi:10.1182/blood-2010-12-326843)

Karvela, M., Helgason, G.V. , and Holyoake, T.L. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 12 (3). pp. 381-392. ISSN 1473-7140 (doi:10.1586/ERA.12.10)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L. , Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukaemia stem cells in combination with imatinib. Cancer Cell, 21 (2). pp. 266-281. ISSN 1535-6108 (doi:10.1016/j.ccr.2011.12.020)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L. , Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell, 21 (2). pp. 266-281. ISSN 1535-6108 (doi:10.1016/j.ccr.2011.12.020)

Marenah, L., Allan, E.K. , Mountford, J.C. , Holyoake, T.L. , Jorgensen, H.G. , and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography . ISSN 0269-3879 (doi:10.1002/bmc.1686) (In Press)

Nieborowska-Skorska, M. et al. (2012) Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood . ISSN 0006-4971 (doi:10.1182/blood-2011-10-385658)

Roy, S., Jorgensen, H.G. , Roy, P., Abed El Baky, M., Melo, J.V., Strathdee, G., Holyoake, T.L. , and Bartholomew, C. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. British Journal of Haematology, 157 (4). pp. 446-456. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2012.09078.x)

Shah, M., Gallipoli, P. , Lyons, J., Holyoake, T.L. , and Jorgensen, H.G. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood, Cells, Molecules and Diseases, 48 (3). pp. 199-201. ISSN 1079-9796 (doi:10.1016/j.bcmd.2012.01.005)

Soliera, A.R. et al. (2012) Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia . ISSN 0887-6924 (doi:10.1038/leu.2012.19)

2011

Ibrahim, A.R., Clark, R.E., Holyoake, T.L. , Byrne, J., Shepherd, P., Apperley, J.F., Milojkovic, D., Szydlo, R., Goldman, J., and Marin, D. (2011) Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica, 96 (12). pp. 1779-1782. ISSN 0390-6078 (doi:10.3324/haematol.2011.049759)

Pellicano, F., and Holyoake, T.L. (2011) Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 208 (11). pp. 2155-2158. ISSN 0022-1007 (doi:10.1084/jem.20112087)

Schmidt, T. et al. (2011) Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1⁺leukemia. Cancer Cell, 19 (6). pp. 740-753. ISSN 1535-6108 (doi:10.1016/j.ccr.2011.05.007)

Allan, E.K., Holyoake, T.L. , Craig, A.R., and Jorgensen, H.G. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia, 25 (6). pp. 985-994. ISSN 0887-6924 (doi:10.1038/leu.2011.55)

Balabanov, S. et al. (2011) Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS ONE, 6 (4). e19164. ISSN 1932-6203

Gallipoli, P., Shepherd, P., Irvine, D. , Drummond, M. , and Holyoake, T.L. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155 (1). pp. 128-130. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2011.08653.x)

Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L. , and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 24 (3). pp. 285-291. ISSN 1011-601X

Marenah, L., Allan, E.K., Mountford, J.C. , Holyoake, T.L. , Jorgensen, H.J. , and Elliott, M.A. (2011) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26 (5). pp. 545-547. ISSN 0269-3879 (doi:10.1002/bmc.1686)

Pellicano, F., Simara, P., Sinclair, A., Helgason, G.V., Copland, M. , Grant, S., and Holyoake, T.L. (2011) The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia, 25 (7). pp. 1159-67. ISSN 0887-6924 (doi:10.1038/leu.2011.67)

Pellicano, F., and Holyoake, T.L. (2011) Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 208 (11). pp. 2155-2158. ISSN 0022-1007 (doi:10.1084/jem.20112087)

Pellicano, F., Sinclair, A., and Holyoake, T.L. (2011) In search of CML stem cells’ deadly weakness. Current Hematologic Malignancy Reports, 6 (2). pp. 82-87. ISSN 1558-8211 (doi:10.1007/s11899-011-0085-y)

Van Etten, R.A. et al. (2011) The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 96 (4). pp. 590-601. ISSN 1592-8721 (doi:10.3324/haematol.2010.035675)

2010

Lidonnici, M.R. et al. (2010) Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Research, 70 (20). pp. 7949-7959. ISSN 0008-5472 (doi:10.1158/0008-5472.CAN-10-1667)

Schemionek, M. et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood, 115 (16). pp. 3185-3195. ISSN 0006-4971 (doi:10.1182/blood-2009-04-215376)

Helgason, V., Young, G., and Holyoake, T. (2010) Targeting chronic myeloid leukemia stem cells. Current Hematologic Malignancy Reports, 5 (2). pp. 81-87. ISSN 1558-8211 (doi:10.1007/s11899-010-0043-0)

Murray, J.A., Khanim, F.L., Hayden, R.E., Craddock, C.F., Holyoake, T.L., Jackson, N., Lumley, M., Bunce, C.M., and Drayson, M.T. (2010) Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). British Journal of Haematology, 149 (1). pp. 65-69. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2009.08055.x)

Hamilton, A., Gallipoli, P. , Nicholson, E., and Holyoake, T.L. (2010) Targeted therapy in haematological malignancies. Journal of Pathology, 220 (4). pp. 404-418. ISSN 0022-3417 (doi:10.1002/path.2669)

Szabo, S.M., Levy, A.R., Davis, C., Holyoake, T.L., and Cortes, J. (2010) A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 13 (1). pp. 103-111. ISSN 10983015 (doi:10.1111/j.1524-4733.2009.00573.x)

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115 (11). pp. 2241-2250. ISSN 0006-4971 (doi:10.1182/blood-2008-06-164582)

Irvine, D. A., Heaney, N. B. , and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24 (1). pp. 1-9. ISSN 0268-960X (doi:10.1016/j.blre.2009.11.002)

Jiang, X. et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116 (12). pp. 2112-2121. ISSN 0006-4971 (doi:10.1182/blood-2009-05-222471)

Milojkovic, D. et al. (2010) Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica-the Hematology Journal, 95 (2). pp. 224-231. ISSN 0390-6078 (doi:10.3324/haematol.2009.012781)

Saglio, G., Kantarjian, H., Holyoake, T., Ranganathan, A., and Cortés, J.E. (2010) Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 10 (6). pp. 443-451. ISSN 2152-2650 (doi:10.3816/CLML.2010.n.077)

Zhang, B. et al. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell, 17 (5). pp. 427-442. ISSN 1535-6108 (doi:10.1016/j.ccr.2010.03.011)

2009

Holyoake, T., and Nicholson, E. (2009) The Chronic Myeloid Leukemia Stem Cell. Clinical Lymphoma, Myeloma and Leukemia, 9 (Suppl.). S376-S381. ISSN 2152-2650 (doi:10.3816/CLM.2009.s.037)

Pellicano, F., Copland, M. , Jorgensen, H.G. , Mountford, J. , Leber, B., and Holyoake, T. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34⁺38^- cells, through activation of protein kinase Cβ. Blood, 114 (19). pp. 4186-4196. ISSN 0006-4971 (doi:10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23 (11). pp. 1999-2006. ISSN 0887-6924 (doi:10.1038/leu.2009.166)

Goldman, J.M., Green, A.R., Holyoake, T.L., Jamieson, C., Mesa, R., Mughal, T., Pellicano, F. , Perrotti, D., Skoda, R., and Vannucchi, A.M. (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia, 23 (10). pp. 1708-1715. ISSN 0887-6924 (doi:10.1038/leu.2009.142)

Drummond, M.W. et al. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23 (6). pp. 1199-1201. ISSN 0887-6924 (doi:10.1038/leu.2009.43)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C. , and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib. Experimental Hematology, 37 (6). pp. 692-700. ISSN 0301-472X (doi:10.1016/j.exphem.2009.02.006)

Allan, E.K., Hamilton, A. , Hatziieremia, S. , Zhou, P., Jorgensen, H.G. , Vigneri, P., and Holyoake, T. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34⁺ chronic myeloid leukaemia cells. Leukemia, 23 (5). pp. 1006-1008. ISSN 0887-6924 (doi:10.1038/leu.2008.367)

Bellodi, C. et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells. Journal of Clinical Investigation, 119 (5). pp. 1109-1123. ISSN 0021-9738 (doi:10.1172/JCI35660)

Foo, J., Drummond, M.W. , Clarkson, B., Holyoake, T., and Michor, F. (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Computational Biology, 5 (9). e1000503 . ISSN 1553-734X (doi:10.1371/journal.pcbi.1000503)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H.G. , and Holyoake, T. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37 (3). pp. 395-401. ISSN 0301-472X (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37 (2). pp. 206-214. ISSN 0301-472X (doi:10.1016/j.exphem.2008.10.013)

2008

Konig, H, Copland, M , Chu, S, Jove, R, Holyoake, T, and Bhatia, R (2008) Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research, 68 (23). pp. 9624-9633. ISSN 0008-5472 (doi:10.1158/0008-5472.CAN-08-1131)

Feldman, EJ et al. (2008) On the use of Lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 22 (9). pp. 1707-1711. ISSN 0887-6924 (doi:10.1038/leu.2008.156)

Shepherd, P, Dhanapala, C, Maguire, C, White, J, Drummond, MW , Holyoake, T, and Johnson, PRE (2008) Successful use of national cancer registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia. Scottish Medical Journal, 53 (3). pp. 8-12. ISSN 0036-9330

Heaney, NB, Copland, M , Stewart, K, Godden, J, Parker, AN, McQuaker, IG, Smith, GM, Crawley, C, Shepherd, P, and Holyoake, TL (2008) Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood, 111 (10). pp. 5252-5255. ISSN 0006-4971 (doi:10.1182/blood-2007-10-118141)

Konig, H, Holtz, M, Modi, H, Manley, P, Holyoake, T, Forman, SJ, and Bhatia, R (2008) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia, 22 (4). pp. 748-755. ISSN 0887-6924 (doi:10.1038/sj.leu.2405086)

Copland, M, Pellicano, F , Richmond, L, Allan, EK, Hamilton, A , Lee, FY, Weinmann, R, and Holyoake, TL (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 111 (5). pp. 2843-2853. ISSN 0006-4971 (doi:10.1182/blood-2007-09-112573)

Konig, H, Holyoake, T, and Bhatia, R (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood, 111 (4). pp. 2329-2338. ISSN 0006-4971 (doi:10.1182/blood-2007-05-092056)

2007

Holyoake, T, and Copland, M (2007) LSC defenses breached by chemical arsenal. Blood, 110 (13). pp. 4138-4139. ISSN 0006-4971

Brazma, D, Grace, C, Howard, J, Melo, JV, Holyoake, T, Apperley, JF, and Nacheva, EP (2007) Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes and Cancer, 46 (11). pp. 1039-1050. ISSN 1045-2257 (doi:10.1002/gcc.20487)

Jorgensen, H.G., and Holyoake, T.L. (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35 (5). pp. 1347-1351. ISSN 0300-5127 (doi:10.1042/BST0351347)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13 (17). pp. 5048-5055. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-07-0919)

Drummond, MW, Balabanov, S, Holyoake, TL, and Brummendorf, TH (2007) Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells, 25 (8). pp. 1853-1861. ISSN 1066-5099 (doi:10.1634/stemcells.2007-0057)

Griffiths, SD, Burthem, J, Unwin, RD, Holyoake, TL, Melo, JV, Lucas, GS, and Whetton, AD (2007) The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Molecular Biotechnology, 36 (2). pp. 81-89. ISSN 1073-6085 (doi:10.1007/s12033-007-0005-5)

Heaney, NCB, and Holyoake, T (2007) Therapeutic targets in chronic myeloid leukaemia. Hematological Oncology, 25 (2). pp. 66-75. ISSN 0278-0232 (doi:10.1002/hon.813)

Allan, E.K., Holyoake, T.L., Jordanides, N.E. , Jorgensen, H.G. , and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34⁺ CML cells. Blood, 109 (9). pp. 4016-4019. ISSN 0006-4971 (doi:10.1182/blood-2006-11-057521)

Halsey, C, Fisher, C, Strathdee, G, Gibson, B, Holyoake, T, Vyas, P, and Graham, G (2007) GATA1 mutational analysis in chronic myeloid leukaemia. British Journal of Haematology, 137 (4). pp. 375-376. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2007.06563.x)

McLintock, LA, Cook, G, Holyoake, T, Jones, BL, Kinsey, SE, and Jackson, GH (2007) High loading dose AmBisome (R) is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica-the Hematology Journal, 92 (4). pp. 572-573. ISSN 0390-6078 (doi:10.3324/haematol.10531)

Balabanov, S et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood, 109 (4). pp. 1701-1711. ISSN 0006-4971 (doi:10.1182/blood-2005-03-037648)

Copland, M, Hamilton, Ashley , and Holyoake, TL (2007) Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL - Response. Blood, 109 (3). p. 1336. ISSN 0006-4971

Heaney, NB, and Holyoake, TL (2007) What is new in chronic myeloid leukaemia? Scottish Medical Journal, 52 (1). pp. 36-41. ISSN 0036-9330

Graham, SM, Vass, JK, Holyoake, T, and Graham, G (2007) Transcriptional analysis of quiescent and proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells, 25 (12). pp. 3111-3120. ISSN 1066-5099 (doi:10.1634/stemcells.2007-0250)

Pellicano, F., and Holyoake, T. (2007) Stem cells in chronic myeloid leukaemia. Cancer Biomarkers, 3 (4-5). pp. 183-191. ISSN 1574-0153

Strathdee, G, Sim, A, Soutar, R, Holyoake, TL, and Brown, R (2007) HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, 28 (2). pp. 299-309. ISSN 0143-3334 (doi:10.1093/carcin/bgl133)

2006

Allan, E.K., Holyoake, T.L., and Jorgensen, H.G. (2006) Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia. Leukemia, 20 (11). pp. 2054-2055. ISSN 0887-6924 (doi:10.1038/sj.leu.2404411)

Fraser, AR, Cook, G, Franklin, IM , Templeton, JG, Campbell, M, Holyoake, TL, and Campbell, JDM (2006) Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity. Journal of Leukocyte Biology, 80 (4). pp. 862-869. ISSN 0741-5400 (doi:10.1189/jlb.0605297)

Holyoake, T.L., Jordanides, N. , Jorgensen, H.G. , and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34⁺ cells and is inhibited by imatinib mesylate. Blood, 108 (4). pp. 1370-1373. ISSN 0006-4971 (doi:10.1182/blood-2006-02-003145)

White, PL et al. (2006) A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. Journal of Molecular Diagnostics, 8 (3). pp. 376-384. ISSN 1525-1578 (doi:10.2353/jmoldx.2006.050120)

Copland, M, Hamilton, A, Eirick, LJ, Baird, JW, Allan, EK, Jordanides, N, Barow, M, Mountford, JC , and Holyoake, TL (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107 (11). pp. 4532-4539. ISSN 0006-4971 (doi:10.1182/blood-2005-07-2947)

Hamilton, A., Elrick, L., Myssina, S., Copland, M. , Jorgensen, H.G. , Melo, J.V., and Holyoake, T.L. (2006) BCR-ABL activity and its response to drugs can be determined in CD34⁺ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia, 20 (6). pp. 1035-1039. ISSN 0887-6924 (doi:10.1038/sj.leu.2404189)

Jorgensen, H.G., Copland, M. , Allan, E.K. , Jiang, X.Y., Eaves, A., Eaves, C., and Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12 (2). pp. 626-633. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-05-0429)

2005

Cummins, M et al. (2005) Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 36 (12). pp. 1065-1069. ISSN 0268-3369 (doi:10.1038/sj.bmt.1705180)

Copland, M., Jorgensen, H.G. , and Holyoake, T.L. (2005) Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology, 10 (5). pp. 349-359. ISSN 1024-5332 (doi:10.1080/10245330500234195)

Jorgensen, H.G., Allan, E.K. , Mountford, J.C. , Richmond, L., Harrison, S. , Elliott, M.A., and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-1146. ISSN 0301-472X (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G. , Mountford, J.C. , and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19 (7). pp. 1184-1191. ISSN 0887-6924 (doi:10.1038/sj.leu.2403785)

Copland, M, Fraser, AR, Harrison, SJ, and Holyoake, TL (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunology Immunotherapy, 54 (4). pp. 297-306. ISSN 0340-7004 (doi:10.1007/s00262-004-0573-1)

Deininger, MWN, and Holyoake, T (2005) Can we afford to let sleeping dogs lie? Blood, 105 (5). pp. 1840-1841. ISSN 0006-4971 (doi:10.1182/blood-2004-12-4764)

Eisterer, W et al. (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia, 19 (3). pp. 435-441. ISSN 0887-6924 (doi:10.1038/sj.leu.2403649)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G. , and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105 (5). pp. 1862-1866. ISSN 0006-4971 (doi:10.1182/blood-2004-08-3373)

Allan, EK, Jordanides, NE, McLintock, LA, Copland, M , Devaney, M, Stewart, K, Parker, A , Johnson, PRE, Holyoake, T, and Jones, BL (2005) Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 128 (4). pp. 578-579. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2004.05333.x)

Jordanides, NE, Allan, EK, McLintock, LA, Copland, M , Devaney, M, Stewart, K, Parker, AN, Johnson, PRE, Holyoake, TL, and Jones, BL (2005) A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplantation, 35 (4). pp. 389-395. ISSN 0268-3369 (doi:10.1038/sj.bmt.1704768)

Jorgensen, H.G., Copland, M. , and Holyoake, T.L. (2005) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 103 (1). pp. 210-211. ISSN 0008-543X (doi:10.1002/cncr.20742)

Kilpatrick, DC, Stewart, K, Allan, EK, McLintock, LA, Holyoake, TL, and Turner, ML (2005) Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Transplantation, 35 (2). pp. 179-181. ISSN 0268-3369 (doi:10.1038/sj.bmt.1704746)

Drummond, M.W., Hoare, S.F. , Monaghan, A., Graham, S.M., Alcorn, M.J., Keith, W.N. , and Holyoake, T.L. (2005) Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia, 19 (3). pp. 381-389. ISSN 0887-6924 (doi:10.1038/sj.leu.2403616)

Jorgensen, H.G., and Holyoake, T.L. (2005) From paradigm to paradox, ponder anew the CML stem cell. Bloodmed Com .

2004

Drummond, MW, Lennard, A, Brummendorf, TH, and Holyoake, TL (2004) Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leukemia and Lymphoma, 45 (9). pp. 1775-1781. ISSN 1042-8194 (doi:10.1080/10428190410001693542)

Harrison, SJ, Johnson, PRE, and Holyoake, T (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scottish Medical Journal, 49 (3). pp. 87-90. ISSN 0036-9330

Osborne, WL, Holyoake, TL, McQuaker, IG, and Parker, A (2004) Fatal peripheral neuropathy following FLA chemotherapy. Clinical and Laboratory Haematology, 26 (4). pp. 295-296. ISSN 0141-9854 (doi:10.1111/j.1365-2257.2004.00613.x)

McLintock, LA, Holyoake, T, and Jones, BL (2004) Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clinical Infectious Diseases, 38 (11). pp. 1648-1649. ISSN 1058-4838 (doi:10.1086/421029)

McLintock, LA, Jordanides, NE, Allan, EK, Copland, M , Stewart, K, Parker, A , Devaney, M, Holyoake, T, and Jones, BL (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal of Haematology, 124 (3). pp. 403-404. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2003.04794.x)

2003

Drummond, MW, Marin, D, Clark, RE, Byrne, JL, Holyoake, TL, and Lennard, A (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. British Journal of Haematology, 123 (3). pp. 479-483. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2003.04599.x)

Kilpatrick, DC et al. (2003) No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clinical and experimental immunology, 134 (2). pp. 279-284. ISSN 0009-9104 (doi:10.1046/j.1365-2249.2003.02284.x)

Drummond, MW, and Holyoake, T (2003) Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 98 (8). pp. 1776-1777. ISSN 0008-543X (doi:10.1002/cncr.11715)

Jorgensen, H.G., Allan, E.K. , Jiang, X., Liakopoulou, E., Richmond, L., Eaves, C.J., Eaves, A.C., and Holyoake, T.L. (2003) Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia, 17 (7). pp. 1430-1432. ISSN 0887-6924 (doi:10.1038/sj.leu.2402967)

Paterson, S.C., Smith, K.D., Holyoake, T.L., and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88 (7). pp. 983-987. ISSN 0007-0920 (doi:10.1038/sj.bjc.6600828)

Chee, YL, Vickers, MA, Stevenson, D, Holyoake, T, and Culligan, J (2003) Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia, 17 (3). pp. 634-635. ISSN 0887-6924 (doi:10.1038/si.leu.2402842)

Drummond, A, Micallef-Eynaud, P, Douglas, WS, Murphy, JA, Hay, I, Holyoake, T, and Drummond, MW (2003) A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec (R)). British Journal of Haematology, 120 (5). pp. 911-913. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2003.04151_4.x)

Drummond, MW, Lush, CJ, Vickers, MA, Reid, FM, Kaeda, J, and Holyoake, T (2003) Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia, 17 (2). pp. 463-465. ISSN 0887-6924 (doi:10.1038/sj.leu.2402814)

Clark, A.D., Jorgensen, H.G. , Mountford, J.C. , and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41 (2-3). pp. 111-131. ISSN 0920-9069 (doi:10.1023/A:1024822722285)

2002

Drummond, MW, Hendry, LM, Maher, E, and Holyoake, T (2002) BCR-ABL fish monitoring of CML: A survey of current UK practice. British Journal of Haematology, 119 (1). pp. 272-273. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2002.38802.x)

Richmond, LJ, Alcorn, MJ, Pearson, C, Cameron, G, Thomas, T, Eaves, CJ, Eaves, AC, and Holyoake, T (2002) CML leukapheresis products can be enriched for CD34(+) cells and simultaneously depleted of CD15(+) cells using a simple Ab cocktail. Cytotherapy, 4 (5). pp. 407-413. ISSN 1465-3249 (doi:10.1080/146532402320775991)

Jorgensen, H.G., Elliott, M., Paterson, S., Holyoake, T.L., and Smith, K. (2002) Further observations on the debated ability of AGP to bind imatinib - Response. Blood, 100 (1). pp. 368-369. ISSN 0006-4971

Holyoake, T, Jiang, X, Drummond, MW , Eaves, AC, and Eaves, CJ (2002) Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia, 16 (4). pp. 549-558. ISSN 0887-6924 (doi:10.1038/sj/leu/2402444)

Pottinger, B, Walker, M, Campbell, M, Holyoake, TL, Franklin, IM , and Cook, G (2002) The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practice. Cytotherapy, 4 (2). pp. 127-135. ISSN 1465-3249 (doi:10.1080/146532402317381839)

Graham, S.M., Jorgensen, H.G. , Allan, E.K. , Pearson, C., Alcorn, M.J., Richmond, L., and Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99 (1). pp. 319-325. ISSN 0006-4971 (doi:10.1182/blood.V99.1.319)

Jorgensen, H.G., Elliott, M.A., Allan, E.K. , Carr, C.E. , Holyoake, T.L., and Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99 (2). pp. 713-715. ISSN 0006-4971 (doi:10.1182/blood.V99.2.713)

2001

Jorgensen, H.G., and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19 (3). pp. 89-106. ISSN 0278-0232 (doi:10.1002/hon.667.abs)

Holyoake, TL, Freshney, MG, Samuel, K, Ansell, J, Watson, GE, Wright, EG, Graham, GJ , and Pragnell, IB (2001) In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice. British Journal of Haematology, 114 (1). pp. 49-56. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2001.02903.x)

Drummond, MW, and Holyoake, TL (2001) Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? Blood Reviews, 15 (2). pp. 85-95. ISSN 0268-960X (doi:10.1054/blre.2001.0152)

Holyoake, T (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: Lessons to be learned from the laboratory. British Journal of Haematology, 113 (1). pp. 11-23. ISSN 0007-1048 (doi:10.1046/j.1365-2141.2001.02558.x)

Campbell, JDM, Cook, G, and Holyoake, T (2001) Evolution of bone marrow transplantation - the original immunotherapy. Trends in Immunology, 22 (2). pp. 88-92. ISSN 1471-4906 (doi:10.1016/S1471-4906(00)01857-3)

Holyoake, T.L., Jiang, X.Y., Jorgensen, H.G. , Graham, S., Alcorn, M.J., Laird, C., Eaves, A.C., and Eaves, C.J. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97 (3). pp. 720-728. ISSN 0006-4971 (doi:10.1182/blood.V97.3.720)

Glimm, H, Eisterer, W, Lee, K, Cashman, J, Holyoake, T, Nicolini, F, Shultz, LD, von Kalle, C, and Eaves, CJ (2001) Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta 2 microglobulin-null mice. Journal of Clinical Investigation, 107 (2). pp. 199-206. ISSN 0021-9738 (doi:10.1172/JCI11519)

Brummendorf, TH, Rufer, N, Holyoake, T, Maciejewski, J, Barnett, MJ, Eaves, CJ, Eaves, AC, Young, N, and Lansdorp, PM (2001) Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. In: Orlic, D, Brummendorf, TH, Sharkis, SJ and Kanz, L (eds.) Hematopoietic Stem Cells 2000 Basic And Clinical Sciences. Series: Annals Of The New York Academy Of Sciences (938). New York Academy of Sciences, New York, pp. 293-304. ISBN 1-57331-295-9